ArticlePharmaceutical research2008
Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging.
Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Acute amyloid-β exposure disrupts insulin signaling in hCMEC/D3 blood-brain barrier endothelial cells.Fluids and barriers of the CNS · 2026Article
- Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery.Biomedicines · 2020Review
- Therapeutic nanoplatforms and delivery strategies for neurological disorders.Nano convergence · 2018Review
- Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review.Nanomaterials (Basel, Switzerland) · 2018Review
- Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane.Neurobiology of disease · 2018Article
- A Metal-Free Method for Producing MRI Contrast at Amyloid-β.Journal of Alzheimer's disease : JAD · 2017Article
- Targeting Malignant Brain Tumors with Antibodies.Frontiers in immunology · 2017Review
- Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.Expert opinion on drug delivery · 2013Review
- Positron emission tomography imaging of fibrillar parenchymal and vascular amyloid-β in TgCRND8 mice.ACS chemical neuroscience · 2013Article
- SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in AβPP/PS-1 transgenic mouse brain.Journal of Alzheimer's disease : JAD · 2013Article
- Magnetic resonance tumor targeting imaging using gadolinium labeled human telomerase reverse transcriptase antisense probes.Cancer science · 2012Article
- Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein.Nanomedicine : nanotechnology, biology, and medicine · 2012Article
- Anti-amyloid-β-mediated positron emission tomography imaging in Alzheimer's disease mouse brains.PloS one · 2012Article
- Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid β protein antibody-coated nanoparticles.Journal of neuropathology and experimental neurology · 2011Article
- Automated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI.Journal of Alzheimer's disease : JAD · 2011Article
- N-terminal engineering of amyloid-β-binding Affibody molecules yields improved chemical synthesis and higher binding affinity.Protein science : a publication of the Protein Society · 2010Article
- In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through?International journal of Alzheimer's disease · 2010Article
- Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies.Biochemistry · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
purposeThe lack of an in vivo diagnostic test for AD has prompted the targeting of amyloid plaques with diagnostic imaging probes. We describe the development of a contrast agent (CA) for magnetic resonance microimaging that utilizes the F(ab')2 fragment of a monoclonal antibody raised against fibrillar human Abeta42
methodsThis fragment is polyamine modified to enhance its BBB permeability and its ability to bind to amyloid plaques. It is also conjugated with a chelator and gadolinium for subsequent imaging of individual amyloid plaques
resultsPharmacokinetic studies demonstrated this 125I-CA has higher BBB permeability and lower accumulation in the liver and kidney than F(ab')2 in WT mice. The CA retains its ability to bind Abeta40/42 monomers/fibrils and also binds to amyloid plaques in sections of AD mouse brain. Intravenous injection of 125I-CA into the AD mouse demonstrates targeting of amyloid plaques throughout the cortex/hippocampus as detected by emulsion autoradiography. Incubation of AD mouse brain slices in vitro with this CA resulted in selective enhancement on T1-weighted spin-echo images, which co-register with individual plaques observed on spatially matched T2-weighted spin-echo image
conclusionsDevelopment of such a molecular probe is expected to open new avenues for the diagnosis of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.